Natural products for the treatment of age-related macular degeneration: New insights focusing on mitochondrial quality control and cGAS/STING pathway.
10.1016/j.jpha.2024.101145
- Author:
Xuelu XIE
1
;
Shan LIAN
1
;
Wenyong YANG
2
;
Sheng HE
3
;
Jingqiu HE
1
;
Yuke WANG
1
;
Yan ZENG
1
;
Fang LU
1
;
Jingwen JIANG
1
Author Information
1. Department of Ophthalmology, West China Hospital and West China School of Public Health and West China Fourth Hospital, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Tianfu Jincheng Laboratory, Chengdu, 610041, China.
2. Department of Neurosurgery, Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, The Third People's Hospital of Chengdu, Chengdu, 610014, China.
3. Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
- Publication Type:Review
- Keywords:
Age-related macular degeneration;
Mitochondrial biogenesis;
Mitochondrial quality control;
Mitophagy;
Phytochemicals;
cGAS/STING
- From:
Journal of Pharmaceutical Analysis
2025;15(5):101145-101145
- CountryChina
- Language:English
-
Abstract:
Age-related macular degeneration (AMD) is a disease that affects the vision of elderly individuals worldwide. Although current therapeutics have shown effectiveness against AMD, some patients may remain unresponsive and continue to experience disease progression. Therefore, in-depth knowledge of the mechanism underlying AMD pathogenesis is urgently required to identify potential drug targets for AMD treatment. Recently, studies have suggested that dysfunction of mitochondria can lead to the aggregation of reactive oxygen species (ROS) and activation of the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) innate immunity pathways, ultimately resulting in sterile inflammation and cell death in various cells, such as cardiomyocytes and macrophages. Therefore, combining strategies targeting mitochondrial dysfunction and inflammatory mediators may hold great potential in facilitating AMD management. Notably, emerging evidence indicates that natural products targeting mitochondrial quality control (MQC) and the cGAS/STING innate immunity pathways exhibit promise in treating AMD. Here, we summarize phytochemicals that could directly or indirectly influence the MQC and the cGAS/STING innate immunity pathways, as well as their interconnected mediators, which have the potential to mitigate oxidative stress and suppress excessive inflammatory responses, thereby hoping to offer new insights into therapeutic interventions for AMD treatment.
